Clinical trial · Observational
IP3R Modulation by Cancer Genes in Mesothelioma
IP3R Modulation by Cancer Genes Bcl-2 & PKM2 in Mesothelioma
NCT03558932CI-TRIAL-00033320unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms and signal transduction
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Mesothelioma | Malignant Mesothelioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pleural biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Pleural biopsy
- timeFrame
- 5 years
- description
- Biopsy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * suspicion of mesothelioma * referral for diagnostic thoracoscopy Exclusion Criteria: * contra-indication for thoracoscopy
References
Publications (0)
Data not yet available
No reference posted for this study.